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There was an error in one of the eGFR estimating equations. This led to errors in [tables 2](#T0001){ref-type="table"}, [3](#T0002){ref-type="table"} and [4](#T0003){ref-type="table"}. The correct equation and revised tables are detailed below:

Therefore: Amongst those with a baseline and subsequent eGFR available, mean eGFR change from baseline at 12 months was --4.4 mL/min (95% Cl −4.9 to −4.0), −2.3 (−2.5 to −2.1), and 2.7 (2.2 to 3.2) in those baseline eGFR ≥90 mL/min; and 11.9 mL/min (11.0 to 12.7), 14.6 (13.5 to 15.7), and 17.8 (16.5 to 19.1), in those with baseline eGFR \<90 mL/min, according to the MDRD, CKD-EPI (n = 11 112), and Cockcroft-Gault (n = 9 283) equations, respectively.Table 2.Kidney function at ART initiation of adult patients starting tenofovir-containing ART with baseline eGFR available from two South African clinicsCharacteristic MDRDCKD-EPICockroft-GaultAll patients    n 13 39613 39611 868eGFR (mL/min) (median, IQR) 98.6 (84.4--115.6)110.4 (96.9--119.6)110.7 (91.4--133.7)Baseline eGFR category (n, %)\>908 769 (66)11 138 (83)9 105 (77) 60--894 221 (32)2 065 (15)2 527 (21) 30--59383 (3)177 (1)225 (2) 15--2918 (0.1)12 (0.1)9 (0.1) \<155 (0.04)4 (0.03)2 (0.02)Baseline and subsequent eGFR    n 11 11211 1129 283eGFR (mL/min) (median, IQR) 98.5 (84.5--115.1)110.4 (97.1--119.6)111.9 (92.8--134.9)Baseline eGFR category (n, %)\>907 273 (66)9 283 (84)7 267 (78) 60--893 541 (32)1 701 (15)1 865 (20) 30--59286 (3)120 (1)146 (2) 15--2912 (0.1)8 (0.1)5 (0.1) \<15000[^1] Table 3.Predicted eGFR change from baseline in patients on tenofovir-containing ART from two South African clinicsChange from baseline (mL/min) Mean (95% CI)3 months6 months12 months24 monthsMDRD‒0.3 (‒0.4 to ‒0.2)‒0.7 (‒0.8 to ‒0.5)‒1.3 (‒1.7 to ‒1.0)‒2.6 (‒3.3 to ‒1.9)n^1^9 2955 2345 5372 486CKD-EPI‒0.3 (‒0.3 to ‒0.2)‒0.5 (‒0.6 to ‒0.4)‒1.0 (‒1.2 to ‒0.8)‒2.0 (‒2.5 to ‒1.6)n^1^9 2955 2345 5372 486Cockcroft-Gault1.0 (0.9 to 1.1)2.0 (1.8 to 2.2)4.0 (3.5 to 4.4)8.0 (7.1 to 8.9)n^1^7 4053 1654 4461 632[^2] Table 4.Predicted eGFR change from baseline according to baseline kidney function in patients on tenofovir-containing ART from two South African clinicsChange from baseline\
Mean (95% confidence interval)3 months6 months12 months24 monthsMDRD    Baseline eGFR ≥90 mL/min‒1.1 (‒1.2 to ‒1.0)‒2.2 (‒2.4 to ‒2.0)‒4.4 (‒4.9 to ‒4.0)‒8.9 (‒9.8 to ‒7.9)n^1^6 0333 4183 6071 558Baseline eGFR \<90 mL/min4.9 (4.5 to 5.3)8.4 (7.8 to 9.1)11.9 (11.0 to 12.7)9.5 (8.4 to 10.5)n^1^3 2621 8161 930928CKD-EPI    Baseline eGFR ≥90 mL/min‒0.6 (‒0.6 to ‒0.5)‒1.1 (‒1.3 to ‒1.0)‒2.3 (‒2.5 to ‒2.1)‒4.6 (‒5.1 to ‒4.2)n^1^7 7314 4134 6212 034Baseline eGFR \<90 mL/min6.2 (3.8 to 6.7)10.6 (9.8 to 11.4)14.6 (13.5 to 15.7)10.7 (9.4 to 12.0)n^1^1 564821916452Cockcroft-Gault    Baseline eGFR ≥90 mL/min0.7 (0.5 to 0.8)1.4 (1.1 to 1.6)2.7 (2.2 to 3.2)5.4 (4.3 to 6.5)n^1^3 8001 6692 352817Baseline eGFR \<90 mL/min6.6 (6.0 to 7.2)11.7 (10.7 to 12.6)17.8 (16.5 to 19.1)18.8 (17.2 to 20.4)n^1^3 6051 4962 094815[^3]

[^1]: CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; MDRD: Modification of Diet in Renal Disease.

[^2]: CI: confidence interval; CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; MDRD: Modification of Diet in Renal Disease.

    1\. Patients who were on tenofovir at the relevant time point, and had at least one eGFR value available within 0.5--4.0 months (3 month time point); 4.1--8.0 months (6 month time point); 8.1--18.0 months (12 month time point); and 18.1--30.0 months (24 month time point). The linear mixed effects model used all eGFR data from all relevant patients to predict changes from baseline.

[^3]: CI: confidence interval; CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; MDRD: Modification of Diet in Renal Disease.

    1\. Patients who were on tenofovir at the relevant time point, and had at least one eGFR value available within 0.5--4.0 months (3 month time point); 4.1--8.0 months (6 month time point); 8.1--18.0 months (12 month time point); and 18.1--30.0 months (24 month time point). The linear mixed effects model used all eGFR data from all relevant patients to predict changes from baseline.
